Nocturia: an overview of evaluation and treatment

Main Article Content

Ari M Bergman
Allison M Sih
Jeffrey P Weiss


nocturia, nocturnal polyuria, lower urinary tract symptoms


Objective: Nocturia is a highly prevalent and bothersome condition. It is associated with multiple medical comorbidities and an increased mortality. Recent investigations have improved understanding of nocturia and its evaluation and treatment. This paper aims to review the classification, etiology, associated medical conditions, evaluation, and treatment of nocturia.

Materials and Methods: A review was conducted surveying published clinical trials, meta-analyses and current clinical practice guidelines on nocturia available as of July 2014. Epidemiology, presentation, evaluation, and treatment recommendations are presented.

Results: Nocturia is a multifactorial condition. Evaluation should include thorough medical history documenting fluid intake, quantified and timed urine output, as well as signs and symptoms of other comorbid conditions. Thorough physical Exam should focus upon detection of conditions contributing to nocturia. Treatment should consist of optimization of underlying medical conditions, behavioral modifications, followed by medications if conservative management fails. Antimuscarinics and alpha blockers have not demonstrated to be effective. Recent studies indicate a possible role of desmopressin in the treatment of nocturia, but concerns about hyponatremia in older patients remain.

Conclusions: Nocturia is a bothersome condition. Treatment of associated co-morbidities is central to treatment. Currently available treatments are available, but efficacy is limited.


Metrics Loading ...
Abstract 21 | HTML Downloads 6 PDF Downloads 12


1. Van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, et al. (2002) The standardization of terminology in nocturia: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 21: 179-183.
2. Tikkinen KA, Johnson TM, Tammela TL, Sintonen H, Haukka J, et al. (2010) Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 57: 488.
3. Van Dijk MM, Wijkstra H, Debruyne FM, de la Rosette JJ, Michel MC (2009) The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int 104: 143.
4. Tikkinen KA, Auvinen A, Johnson TM 2nd, Weiss JP, Keränen T, et al. (2009) A systemic evaluation of factors associated with nocturia – the population-based FINNO study. Am J Epidemiol. 170: 361-8.
5. Tikkinen KA, Tammela TL, Huhtala H, Auvinen A (2006) Is nocturia equally common among men and women? A population based study in Finland. J Urol 175: 596-600.
6. Malmsten UG, Milsom I, Molander U, et al. (1997) Urinary incontinence and lower urinary tract symptoms: an epidemiological study of men aged 45 to 99 years. J Urol 158:1733.
7. Bosch JL, Weiss JP (2013) The prevalence and causes of nocturia. J Urol 189: S86-92.
8. Fitzgerald MP, Litman HJ, Link CL, McKinlay JB, Investigators BS (2007) The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol 177: 1385-1389.
9. Weiss JP, Weinberg AC, Blaivas JG (2008) New aspects of the classification of nocturia. Curr Urol Rep 9: 362-367.
10. Van Doorn B, Kok ET, Blanker MH, Westers P, Ruud Bosch JL (2014) Determinants of nocturia: the Krimpen Study. J Urol 191: 1034-1039.
11. Andersson KE, Nomiya M, Sawada N, Yamaguchi O. Pharmacological treatment of chronic pelvic ischemia. Ther Adv Urol. 2014 Jun;6(3):105-14.
12. Sakakibara R, Panicker J, Fowler CJ, Tateno F, Kishi M, Tsuyusaki Y, Yamanishi T, Uchiyama T, Yamamoto T, Yano M. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol. 2014 Jan;21(1):33-8.
13. Zeitzer JM, Bliwise DL, Hernandez B, Friedman L, Yesavage JA. Nocturia compounds nocturnal wakefulness in older individuals with insomnia. J Clin Sleep Med. 2013 Mar 15;9(3):259-62.
14. Fitzgerald MP, Litman HJ, Link CL, McKinlay JB, BACH Survey Investigators (2007) The Association of Nocturia with Cardiac Disease, Diabetes, Body Mass Index, Age, Diuretic Use: Results from the BACH survey. J Urol 177: 1385-1389.
15. Yoshimura K, Terada N, Matsui Y, Terai A, Kunukawa N, et al. (2004) Prevalence of and risk factors for nocturia: Analysis of a health screening program. Int J Urol 11: 282-287.
16. Hirayama A, Torimoto K, Mastusita C, Okamoto N, Morikawa M, et al. (2013) Evaluation of factors influencing the natural history of nocturia in elderly subjects: results of the Fujiwara-kyo Study. J Urol 189: 980-986.
17. Tandeter H, Gendler S, Dreiher J, Tarasiuk A (2011) Nocturic episodes in patients with benign prostatic enlargement may suggest the presence of obstructive sleep apnea. J Am Board Fam Med 24: 146-151.
18. Margel D, Shochat T, Getzler O, Livne PM, Pillar G (2006) Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea. Urology 67: 974-977.
19. TaKoskimäki J, Shiri R, Tammela T, Häkkinen J, Hakama M, et al. (2008) Depressive symptoms increase the incidence of nocturia: Tempere Aging Male Urologic Study (TAMUS). J Urol 179: 1897-901.
20. Kupelian V, Fitzgerald MP, Kaplan SA, Norgaard JP, Chiu GR, et al. (2011) Association of nocturia and mortality: Results from the third National Health and Nutrition Examination Survey. J Urol 185: 571-577.
21. Johnson TM, Endeshaw Y, Nagamia Z, et al. (2005) A multicomponent intervention for nocturia in men. J Am Geriatr Soc 53:S94.
22. Cho SY, Lee SL, Kim IS, Koo DH, Kim HJ, et al. (2012) Short-term effects of systematized behavioral modification program for nocturia: A prospective study. Neurourol Urodyn 31: 64-68.
23. Johnson TM 2nd, Jones K, Williford WO, Kutner MH, Issa MM, et al. (2003) Changes in nocturia from medical management of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 170: 145-148.
24. Johnson TM, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, et al. (2007) The effect of doxazosin, finasteride, and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 178: 2045-2050.
25. Johnson TM, 2nd, Burgio KL, Redden DT, Wright KC, Goode PS (2005) Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 53: 846-850.
26. Yokoyama O, Yamaguchi O, Kakizaki H, Itoh N, Yokota T, et al. (2011) Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol 186: 170-174.
27. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z, et al. (2006) Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 67: 731-736.
28. Weiss JP, Jumadilova Z, Johnson TM, FitzGerald MP, Carlsson M, et al. (2013) Efficacy and safety of flexible-dose fesoterodine in men and women with overactive bladder symptoms, including nocturnal urinary urgency. J Urol 189: 1396-1401.
29. Moon DG, Jin MH, Lee JG, Kim JJ, Kim MG, et al. (2004) Antidiuretic hormone in elderly male patients with severe nocturia: a circadian study. BJU Int 94: 571-575.
30. van Kerrebroeck P, Rezapour M, Cortesse A, Thuroff J, Riis A, et al. (2007) Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur Urol 52: 221-229.
31. Juul KV, Klein BM, Norgaard JP (2013) Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn 32: 363-370.
32. Weatherall M (2004) The risks of hyponatremia in older adults using desmopressin for nocturia: a systemic review and meta-analysis. Neurol Urodyn, 23: 302-305.
33. Song M, Hong BS, Chun JY, Han JY, Choo MS (2014) Safety and efficacy of desmopressin for the treatment of nocturia in elderly patients: a cohort study. Int Urol Nephrol 46: 1495-1499.
34. Simaioforidis V, Papatsoris AG, Chrisofos M, Koritsiadis S, et al. (2011) Tamsulosin versus transurethral resection of the prostate: effect on nocturia as a result of benign prostatic hyperplasia. Int J Urol 18: 243-248.